Meeting
2016 Genitourinary Cancers Symposium
Evaluating abiraterone responses in African Americans with metastatic CRPC.
Authors
Michael D. Stolten
Tulane University School of Medicine, New Orleans, LA
Michael D. Stolten , Elisa M. Ledet , Jeffrey R. Guccione , Allison H. Feibus , Brian E. Lewis , Jonathan L. Silberstein , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 244)
DOI
10.1200/jco.2016.34.2_suppl.244
Abstract #
244
Poster Bd #
K15
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Characterization of abiraterone responses in African American castrate resistant prostate cancer.
First Author: Michael Stolten
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb